Eisai's Late-stage Pipeline

Strategy: Eisai inspired to MorphOf the 17 new molecular entities in Phase II to registration in Eisai Co. Ltd.'s pipeline, 10 (59%) came from in-licensing deals or Eisai's acquisitions of MGI Pharma ...